SLSSell-54% SELLAS Life Sciences Group, Inc. SELLAS Life Sciences develops licensed cancer drugs, led by the galinpepimut-S (GPS) vaccine for acute myeloid leukaemia and the kinase inhibitor… Health Care · Target $8.77Latest: Initiation, Nov 19, 2026
SLSSellTarget $8.77InitiationNov 19, 2026 Positive Phase 3 survival data cannot justify a $3.9bn valuation; initiate at Sell We initiate on SELLAS Life Sciences at Sell with an $8.77 12-month target, or −54.2% total return from $19.15. Read the report →